tbuckley/cabot-search huggingface dataset:
Abstract 10845: Spontaneous Coronary Artery Dissection as the Primary Presentation of Ana-Negative Lupus
Authors: Sumon Roy, Sandra Johnson, Seema Patel, Barbara D Lawson
Journal: Circulation (2021)

Introduction: Spontaneous coronary artery dissection (SCAD) is a rare cause of myocardial infarction that most often occurs in middle-aged women with minimal classic risk factors and has been associated with hormonal imbalance, pregnancy, fibromuscular dysplasia, and connective tissue disease. SCAD has been seldom associated with systemic lupus erythematosus (SLE). SLE patients typically exhibit positive ANA titers. Here, we present the first known case report of a patient with SCAD as the primary presentation of ANA-negative SLE. Case Presentation: A 55-year-old female with migraines presented for elective kidney donation. Surgery was complicated by hemodynamic instability and NSTEMI. Transthoracic echocardiogram (TTE) showed preserved ejection fraction and hypokinesis of the basal to mid lateral and septal walls. Coronary angiogram was suspicious for type 3 SCAD of the left anterior descending (LAD) coronary artery, and given the clinical course, a coronary wire was advanced to perform intracoronary hemodynamic assessment, which was negative for atherosclerotic disease. Upon retraction of the wire, there was no flow in the LAD, consistent with propagated SCAD, leading to PEA arrest. After resuscitation, the LAD was stented. Repeat TTE showed preserved ejection fraction and normal wall motion. She was discharged on aspirin and clopidogrel. At cardiology outpatient follow up, the patient described symptoms consistent with Raynaud’s phenomenon and was referred to Rheumatology. She ultimately also developed hair loss, oral ulcers, joint pain, photosensitivity, malar erythema, and Sicca symptoms. Her anti-double stranded DNA antibodies were strongly positive twice, but remarkably, ANA screening was repeatedly negative. However, taken together, she met classification criteria for SLE diagnosis. Conclusions: SLE can present in highly atypical fashion, clinically and serologically, as with this case. SCAD is rare, but this case highlights the importance of keeping it on the differential for myocardial infarction, particularly in female patients with non-traditional risk factors or rheumatological disease. This case also exemplifies there should be a low clinical threshold for rheumatological workup in patients diagnosed with SCAD.
SLC5A3 Transports Myo-Inositol to Support the Growth of Acute Myeloid Leukemia
Authors: Shan Lin, Nastassja K. Scheidegger, Gabriela Alexe, Bo Kyung A. Seong, Neekesh V Dharia, Caroline Wechsler, Guillaume Kugener, Amanda L Robinchaud, Amy Conway, Biniam Adane, Scott Younger, Federica Piccioni, Lynn Lee, Mark Wunderlich, Kimberly Stegmaier
Journal: Blood (2021)
Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)
Authors: Jan Frederic Weller, Louisa Kaufmann, Claudia Lengerke, Jürgen Finke, Johannes Schetelig, Uwe Platzbecker, Hermann Einsele, Dietrich W. Beelen, Christoph Faul, Matthias Stelljes, Peter Dreger, Igor Wolfgang Blau, Gerald Wulf, Johanna Tischer, Christof Scheid, Ahmet Elmaagacli, Helga Neidlinger, Sandra Frank, Martin Bornhäuser, Wolfgang A Bethge, Katharina Fleischhauer, Nicolaus Kröger, Maximilian Christopeit
Journal: Blood (2021)
Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience
Authors: Sara Arcudi, Alessandro Ciavarella, Roberta Gualtierotti, Sonia Marino, Marco Boscarino, Simona Siboni, Eugenia Biguzzi, Lucia Schiavone, Cristina Novembrino, Carla Valsecchi, Flora Peyvandi
Journal: Blood (2021)
Abstract IA-002: Dendritic cell corner stone of tumor immunity in PDAC
Authors: David G. DeNardo
Journal: Cancer Research (2021)

Abstract T cell-directed immunotherapies have not been effective for the majority of pancreatic cancer patients, in part, due to our limited understanding of how T cell immunity is subverted in this disease. We sought to identify mechanisms for this failure using spontaneous mouse models. We report that endogenous antigen-specific responses in PDAC are aberrant due to a scarcity of dendritic cells, which favors the expansion of tumor-promoting TH17 immunity. Restoring cDCs in pancreatic cancer can enhance CD8+ T cell and TH1 activity to ultimately help control disease. These findings expand our understanding of T cell ineffectiveness in pancreatic cancer, and propose combinatorial strategies to modulate cDCs in conjunction with existing therapies for pancreatic cancer and similar solid malignancies. Citation Format: David G. DeNardo. Dendritic cell corner stone of tumor immunity in PDAC [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr IA-002.
SLN124, a GalNAc Conjugated 19-Mer Double-Stranded SiRNA Reduces Iron and Increases Hepcidin Levels of Healthy Volunteers in a Phase 1 Clinical Study
Authors: John B. Porter, Alison Scrimgeour, Alberto Martinez, Leo James, Manuela Aleku, Rosamund Wilson, Martina U. Muckenthaler, Ute Schaeper, Giles V Campion
Journal: Blood (2021)
Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy
Authors: Khushnuma Mullanfiroze, Giorgio Ottaviano, Avijeet K Mishra, Maria Gabelli, Arina Lazareva, Saskia Burridge, Susan Farish, Jan Chu, Kirsty Sharplin, David I. Marks, Maeve A O'Reilly, Emma Nicholson, Kelly Watts, Denise Bonney, Danny Cheng, Jack Bartram, Sujith Samarasinghe, Vesna Pavasovic, Anupama Rao, Philip Ancliffe, Ajay Vora, Giovanna Lucchini, Robert Chiesa, Paul Veys, Kanchan Rao, Persis J Amrolia, Sara Ghorashian
Journal: Blood (2021)
Randomized Phase II Study of All-<i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status
Authors: Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Crysandt, Edgar Jost, Felicitas Thol, Michael Heuser, Katharina S. Goetze, Richard F. Schlenk, Helmut R. Salih, Marcus M. Schittenhelm, Gerhard Heil, Carsten Schwaenen, Carsten Müller-Tidow, Wolfram Brugger, Andrea Kündgen, Ulrich Germing, Maike de Wit, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Jürgen Krauter, Gesine Bug, Annette M. May, Ralph Wäsch, Justus Duyster, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Björn Hackanson, Michael Lübbert
Journal: Blood (2021)
Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study
Authors: Yongfu Yu, Melissa Soohoo, Henrik Toft Sørensen, Jiong Li, Onyebuchi A. Arah
Journal: Diabetes Care (2021)

OBJECTIVE To evaluate associations between gestational diabetes mellitus (GDM) and various incident cardiovascular disease (CVD) end points, considering the effects of the mediating role of type 2 diabetes and shared environmental/familial factors. RESEARCH DESIGN AND METHODS This population-based cohort study included 10,02,486 parous women in Denmark during 1978–2016. We used Cox regression to 1) examine the associations of GDM with overall and type-specific CVDs using full-cohort and sibling-matched analysis, 2) quantify the impact of type 2 diabetes after GDM using mediation analysis, and 3) assess whether these associations were modified by prepregnancy obesity or maternal history of CVD. RESULTS Women with a history of GDM had a 40% increased overall CVD risk (hazard ratio [HR] 1.40, 95% CI 1.35–1.45). Sibling-matched analyses yielded similar results (HR 1.44, 95% CI 1.28–1.62). The proportion of association between GDM and overall CVD explained by subsequent type 2 diabetes was 23.3% (15.4–32.8%). We observed increased risks of specific CVDs, including 65% increased stroke risk and more than twofold risks for myocardial infarction, heart failure, and peripheral artery disease. The elevated overall risks were more pronounced among women with GDM and prepregnancy obesity or maternal history of CVD. CONCLUSIONS A history of GDM was associated with increased risks of overall and specific CVDs. Increased risks were partly explained by subsequent type 2 diabetes, and the need to identify other pathways remains important. Continuous monitoring of women with a history of GDM, especially those with prepregnancy obesity or maternal history of CVD, may provide better opportunities to reduce their cardiovascular risk.
Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma <i> (</i>LBCL): Results from the Phase 3 Transform Study
Authors: Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar
Journal: Blood (2021)
Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax
Authors: Evan C. Chen, Yiwen Liu, Eric S. Winer, Marlise R. Luskin, Martha Wadleigh, Andrew A. Lane, Rahul S. Vedula, Coleman Lindsley, Kevin Copson, Anne Charles, Donna S. Neuberg, Nicolas C. Issa, Daniel J. DeAngelo, Richard M. Stone, Jacqueline S. Garcia
Journal: Blood (2021)
Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D
Authors: Thomas J. Hwang, Xuanzi Qin, Nancy L. Keating, Haiden A. Huskamp, Stacie B. Dusetzina
Journal: JAMA Oncology (2021)

This cross-sectional study examines patients’ out-of-pocket costs with and without rebate pass-through to point-of-sale prices for cancer drugs under Medicare Part D.
Bilateral Trigeminal Myokymia in Chronic Inflammatory Demyelinating Polyneuropathy With Systemic Lupus Erythematosus–Sjögren Overlap Syndrome
Authors: Arpan Dutta, Subhadeep Gupta, Biman Kanti Ray
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
A Meta-Analysis of Hypersensitivity to Pegylated Escherichia coli Asparaginase Used As First-Line Treatment in Contemporary Pediatric Acute Lymphoblastic Leukemia Protocols
Authors: Leiah Brigitha, Marta Fiocco, Rob Pieters, Birgitte Klug Albertsen, Gabriele Escherich, Elixabet Lopez-Lopez, Veerle Mondelaers, Ajay Vora, Lynda M. Vrooman, Kjeld Schmiegelow, Inge M. Van Der Sluis
Journal: Blood (2021)
Outcome of Children with Wiskott-Aldrich Syndrome (WAS) Given TCR Alpha-Beta/CD19 Depleted Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Haploidentical Relative
Authors: Mattia Algeri, Daria Pagliara, Valentina Bertaina, Giuseppina Li Pira, Elia Girolami, Giovanna Leone, Antonella Meschini, Emilia Boccieri, Federica Galaverna, Marialuigia Catanoso, Francesca Del Bufalo, Pietro Merli, Franco Locatelli
Journal: Blood (2021)
Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group
Authors: Atsushi Sato, Yoshihiro Hatta, Chihaya Imai, Koichi Oshima, Yasuhiro Okamoto, Takao Deguchi, Yoshiko Hashii, Takashi Fukushima, Toshinori Hori, Nobutaka Kiyokawa, Motohiro Kato, Shoji Saito, Kenichi Anami, Tatsuhiro Sakamoto, Akiko Kada, Akiko M Saito, Atsushi Manabe, Hitoshi Kiyoi, Itaru Matsumura, Keizo Horibe, Katsuyoshi Koh, Yasushi Miyazaki, Arata Watanabe
Journal: Blood (2021)
Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay
Authors: Markus D Lacher, Michelle A Richardson, Steven A Schaffert, Ryosuke Kita, Marianne T Santaguida, Erica K Anderson, Jordan Roselli, Wade Anderson, Arisa Paul, Christine Gu, Kathryn Vanderlaag, Zhihong Zeng, Abhishek Maiti, Courtney D. DiNardo, Marina Konopleva
Journal: Blood (2021)
Mycobiome Supporting Diet to Reduce Gastrointestinal (GI)Toxicity Associated with Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)
Authors: Ehsan Malek, Farhad Sanati, Amanda Lauren, Leland Metheny, Molly Gallogly, Mauricio Retuerto, Mahmoud Ghannoum
Journal: Blood (2021)
Abstract 11622: Resolution of Inflammation via Rvd1/fpr2 Signaling in Abdominal Aortic Aneurysms
Authors: Amanda Filiberto, Victoria Leroy, Zachary Ladd, Gang Su, Craig Elder, Eric Pruitt, Sara Hensley, Guanyi Lu, Ali Zarrinpar, Ashish Sharma, Gilbert R R Upchurch
Journal: Circulation (2021)

Introduction: Resolvin D1 (RvD1) is derived from a ω-3 polyunsaturated fatty acid and is involved in the resolution phase of inflammation during abdominal aortic aneurysm (AAA) formation. Hypothesis: The aim of this study was to decipher the protective role of RvD1 via formyl peptide receptor 2 (FPR2) receptor signaling in attenuating AAA formation. Methods: C57BL/6 (WT) and FPR2 -/- mice (8-12 week old) underwent treatment with topical elastase or heat-inactivated elastase (control). Separate groups of mice were administered RvD1 (100ng/kg) or saline i.p. daily from day(d)1 to d13 and aortic diameter was measured by video micrometry on d14. mRNA quantification of FPR2 expression in aortic tissue was performed by RT-PCR on d7, 14 and 21. Human aortic tissue from AAA patients and controls (organ transplant donors) were analyzed for quantification of FPR2 expression. Data is presented as mean ± SEM and statistical analysis was performed by using Mann-Whitney test for phenotype or Wilcoxon Signed Rank Test for gene expression data. Results: Elastase-treated WT mice had significantly increased aortic diameter compared to controls (127±8% vs. 1± 0.6%; p&lt;0.0001). Importantly, elastase-treated FPR2 -/- had a significant increase in aortic diameter compared to elastase-treated WT mice (165±16% vs. 127± 8%; p=0.03). RvD1 treatment attenuated AAA formation in WT mice, but not FPR2 -/- mice, on d14 (56± 10% vs.121± 8%; p&lt;0.0001). Immunohistology documented decreased elastin and smooth muscle cell α-actin expression, as well as increased neutrophil and macrophage infiltration in FPR2 -/- mice compared to WT mice, after respective treatments with RvD1. Elastase-treated WT mice had significantly increased FPR2 receptor mRNA expression compared to respective controls on d7, d14, and d21. Human AAA tissue demonstrated significantly decreased FPR2 mRNA expression compared to controls (p=0.02). Conclusions: This data identifies the role of FPR2 in dysregulation of inflammation-resolution during AAA pathogenesis. Immunomodulation of FPR2 signaling by exogenous RvD1 identifies a novel mechanism in resolution of aortic inflammation and vascular remodeling during AAA pathogenesis.
Abstract 13754: Association of Cumulative Excess Adiposity With Heart Failure With Preserved and Reduced Ejection Fraction: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Admasu Y Wondmagegn, Justin B Echouffo Tcheugui, Sui Zhang, Kavita Sharma, Kuni Matsushita, Amil M Shah, Laura R Loehr, VIJAY NAMBI, Roberta Florido, Patricia Chang, Christie M Ballantyne, Josef Coresh, Chiadi E Ndumele
Journal: Circulation (2021)

Background: Prior studies suggest that obesity, measured at a single time point, has a stronger association with heart failure with preserved ejection fraction (HFpEF) than heart failure with reduced ejection fraction (HFrEF). Longstanding obesity is associated with both diastolic and systolic dysfunction, but there is scarce data on the association of cumulative adiposity with risks for HFpEF and HFrEF. Hypothesis: Higher cumulative adiposity is associated with increased risk for both HFpEF and HFrEF. Methods: We performed a prospective analysis of 8,895 individuals (mean age 63, 57% women, 19% Black adults) without HF or coronary heart disease (CHD) who attended ARIC Visit 4 (1996-99). We calculated cumulative excess body-mass index (BMI) years from age 25 to Visit 4 by centering the BMI variable at 25 kg/m2 at each of the first 4 ARIC visits and at age 25 (self-reported), and multiplying the average BMI by the number of years from age 25 to Visit 4. Cumulative excess BMI years were categorized into quartiles. The outcomes were cases of incident HFpEF (EF ≥50%) and HFrEF (EF &lt;50%) during the period of HF adjudication in ARIC (1/1/2005-12/31/2019); we excluded those with HF prior to 2005. We used Cox models to calculate incidence rates and estimate hazard ratios (HRs) for the associations of cumulative excess BMI years with incident HFpEF and HFrEF, adjusting for covariates including incident CHD. Results: There were 554 HFpEF and 482 HFrEF events over 14 years of follow-up. Higher quartiles of cumulative excess BMI years were associated with greater incidence of HFpEF and HFrEF (Table). Compared to the lowest quartile, the highest quartile of cumulative excess BMI years was associated with greater risk for HFpEF (HR: 1.57, 95% CI 1.22-2.03) and HFrEF (1.50, 95% CI 1.13-1.99). Conclusions: Excess cumulative weight is associated with similarly increased risks of HFpEF and HFrEF, indicating the importance of obesity prevention for reducing the risks for different subtypes of HF.
National Trends and Disparities in Hospitalization for Acute Hypertension Among Medicare Beneficiaries (1999–2019)
Authors: Yuan Lu, Yun Wang, Erica S. Spatz, Oyere Onuma, Khurram Nasir, Fatima Rodriguez, Karol E. Watson, Harlan M. Krumholz
Journal: Circulation (2021)

In the past 2 decades, hypertension control in the US population has not improved and there are widening disparities. Little is known about progress in reducing hospitalizations for acute hypertension.We conducted serial cross-sectional analysis of Medicare fee-for-service beneficiaries age 65 years or older between 1999 and 2019 using Medicare denominator and inpatient files. We evaluated trends in national hospitalization rates for acute hypertension overall and by demographic and geographical subgroups. We identified all beneficiaries admitted with a primary discharge diagnosis of acute hypertension on the basis of International Classification of Diseases codes. We then used a mixed effects model with a Poisson link function and state-specific random intercepts, adjusting for age, sex, race and ethnicity, and dual-eligible status, to evaluate trends in hospitalizations.The sample consisted of 397 238 individual Medicare fee-for-service beneficiaries. From 1999 through 2019, the annual hospitalization rates for acute hypertension increased significantly, from 51.5 to 125.9 per 100 000 beneficiary-years; the absolute increase was most pronounced among the following subgroups: adults ≥85 years (66.8-274.1), females (64.9-160.1), Black people (144.4-369.5), and Medicare/Medicaid insured (dual-eligible, 93.1-270.0). Across all subgroups, Black adults had the highest hospitalization rate in 2019, and there was a significant increase in the differences in hospitalizations between Black and White people from 1999 to 2019. Marked geographic variation was also present, with the highest hospitalization rates in the South. Among patients hospitalized for acute hypertension, the observed 30-day and 90-day all-cause mortality rates (95% CI) decreased from 2.6% (2.27-2.83) and 5.6% (5.18-5.99) to 1.7% (1.53-1.80) and 3.7% (3.45-3.84) and 30-day and 90-day all-cause readmission rates decreased from 15.7% (15.1-16.4) and 29.4% (28.6-30.2) to 11.8% (11.5-12.1) and 24.0% (23.5-24.6).Among Medicare fee-for-service beneficiaries age 65 years or older, hospitalization rates for acute hypertension increased substantially and significantly from 1999 to 2019. Black adults had the highest hospitalization rate in 2019 across age, sex, race and ethnicity, and dual-eligible strata. There was significant national variation, with the highest rates generally in the South.
Advances in Appropriate Postoperative Triage and the Role of Real-time Machine-Learning Models: The Goldilocks Dilemma
Authors: Ara Ko, Sherry M. Wren
Journal: JAMA Network Open (2021)

Tyler J. Loftus, MD; Matthew M. Ruppert, BS; Tezcan Ozrazgat-Baslanti, PhD; Jeremy A. Balch, MD; Philip A. Efron, MD; Patrick J. Tighe, MD; William R. Hogan, MD; Parisa Rashidi, PhD; Gilbert R. Upchurch Jr, MD; Azra Bihorac, MD
IFN-Gamma Producing Regulatory T Cells Counterbalance T Cell-Mediated Injury to the Intestinal Stem Cell Compartment in Mice and Humans
Authors: Sascha Göttert, Julius Clemens Fischer, Gabriel Eisenkolb, Erik Thiele Orberg, Dirk Busch, Sebastian Jarosch, Ernst Holler, Thomas Engleitner, Lena Klostermeier, Caroline Walther, Laura Lansink Rotgerink, Sophie Nefzger, Marianne Reiser, Katja Steiger, Roland Rad, Stefanie E. Combs, Florian Bassermann, Simon Heidegger, Hendrik Poeck
Journal: Blood (2021)
Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study
Authors: Maël Heiblig, Marcela A Ferrada, Mathieu Gerfaud-Valentin, Thomas Barba, Arsène Mékinian, Matthew Koster, Henrique Coelho, Gaelle Fossard, Fiorenza Barraco, Lionel Galicier, Boris Bienvenu, Pierre Hirsch, Guillaume Vial, Anne Blandine Boutin, Guillaume Le guenno, Adrien Bigot, Kenneth Warrington, Tanaz Kermani, Yvan Jamilloux, Peter C Grayson, Bhavisha A. Patel, David B. Beck, Pierre Fenaux, Pierre Sujobert
Journal: Blood (2021)
Head of BMA committee steps down in row over patients’ access to GPs
Authors: Gareth Iacobucci, Elisabeth Mahase
Journal: BMJ (2021)

Richard Vautrey stepped down as UK and England chair of the BMA’s General Practitioners Committee (GPC) last week, after a split within the committee over its approach to working with the government came to a head.

Vautrey, a GP in Leeds, had been chair of the GPC for four years and part of the committee’s negotiating and executive team since 2004. Announcing his departure on 1 November he said, “Being chair of the BMA’s GP committee has been the greatest privilege and honour. I’ve decided that the forthcoming first meeting of our delayed annual session is the right time for a new chair to take on this role.”

Vautrey’s departure came after growing tension between the GPC executive and the committee in recent months, with some committee members calling for the leadership to take a tougher stance in negotiations with NHS England and the government.

Internal committee correspondence seen by The BMJ shows that just before his departure was announced some committee members proposed an …